

ANGLE PLC

23:33 17 Nov 2011

Something for everyone at next Wednesday's Proactive Investors One2One Forum in London: ANGLE, Deltex Medical, Silence Therapeutics and Stanley Gibbons

Exciting barely covers it. We have a line-up that offers something for everyone at the Proactive Investors One2One Forum in London next Wednesday 23rd November. ANGLE, whose star really is in the ascendancy, will be joined by Deltex Medical, Silence Therapeutics and Stanley Gibbons.

Each has attracted an incredible amount of interest. So if you haven't signed up already, you really need to do so soon to avoid disappointment. Please click here to register for the event.

The recent noise around intellectual property group ANGLE (LON:AGL) has been incredible and has followed the success of a breakthrough cancer screening device developed by its Parsortix business.

The longest established of London's quoted IP companies, there is more to ANGLE than this one business. So this is a stock that will appeal to those following IP Group (LON:IPO) and Fusion IP (LON:FIP).

Meanwhile, Parsortix will appeal to those investors interested in medical technology, so this is companies such as Avacta (LON:AVCT) and Sphere Medical (LON:SPHR).

Meanwhile, ANGLE's Novocellus business will be of interest to those people following cutting edge healthcare firms such as Axis-Shield (LON:ASD).

In Geomerics the group has an investment at the very cutting edge of video game technology whose Enlighten middleware is included in titles such as Battlefield 3.

So ANGLE is three separate investments in one.

That said the real driver of the share price has been the development of Parsortix and its blood monitor that picks up the early signs of cancer.

The recent spate of positive announcements charting the device's development has driven up ANGLE's value by 200 per cent.

Although still in its infancy, Parsortix technology may ultimately have the ability to identify all the hard tumour types, without knowing in advance which cancer is expected.

This is a step on from the existing means of identifying circulating cancer cells,

Price: 61

Market Cap: £105.38 m

1 Year Share Price Graph



December 2018 June 2019 December 20

Share Information

Code: AGL

Listing: AIM

52 week High Low
85 38

Sector: Pharma & Biotech

Website: www.angleplc.com

Company Synopsis:

ANGLE PLC develops products for use in rare cell diagnostics that enable early, accurate identification of an individual's condition for the prevention, treatment, and monitoring of disease.

action@proactiveinvestors.com.au

where the tests are specific to each cancer type and even then are not totally reliable.

"We think ours has a much more universal application - hopefully to all solid tumours," chief executive Andrew Newland said recently.

Followers of LidCo (LON:LID) will probably already have half an eye on Deltex Medical (LON:DEMG), which is aiming to get its revolutionary CardioQ-ODM blood monitoring system accepted by health services and hospitals around the world.

Recent updates from the company reveal it is making good headway in achieving this aim in the UK.

CardioQ-ODM (Oesophageal Doppler Monitor) is a blood monitoring system that requires a new disposable probe every time the system is used on a new patient, meaning that Deltex gets a consumables-driven revenue stream as well as income from sales of the device itself.

After selecting CardioQ as one of the first products for review by its newly-established Medical Technologies Advisory Committee, the device received the backing of the UK's health spending watchdog NICE.

NICE estimates that its recommendation applies to 837,000 surgical patients each year in the NHS in England alone.

It is estimated the device could save the NHS £1 billion a year. Yet the potential of CardioQ is only just being recognised by healthcare providers and the market.

Turning from healthcare to biotechnology, and specifically Silence Therapeutics (LON:SLN), our recent article describes the group as leaner and fitter than it ever has been.

And more to the point it is fully funded to develop a potentially breakthrough treatment for cancer.

The latest update on its phase I clinical trials, released earlier this month, made encouraging reading.

This is a stock that will appeal to fans of Sareum Holdings (LON:SAR) and ValiRx (LON:VAL), who understand early-stage biotech investment.

Finally, if alternative investment is your bag then you are no doubt following two quoted companies at the cutting edge of this specialist area.

One would be Noble Investments (LON:NBL), which specialises in coins, and the other is undoubtedly Stanley Gibbons, whose shop on the Strand is a Mecca for stamp collectors.

The recent opening of an office in Hong Kong reveals Stanley Gibbons going international.

China is a real hotspot for philately and a potentially huge market for a

company whose name resonates worldwide.

Bringing us up to speed on the group's expansion plans and the success of its investment products will be chief executive Michael Hall.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).